Nanologica (NICA) Q4 2025 earnings summary

Executive summary

• Net sales for 2025 increased 45% year-over-year to SEK 21.1 million, but production constraints limited further growth.

• Operating loss for the year improved to SEK -46.8 million from SEK -59.3 million in 2024.

• Major acquisition of Ardena Södertälje AB (to be renamed Syntagon AB) strengthens production capacity and is expected to boost earnings and cash flow from 2026.

• Rights and directed share issues totaling SEK 96.2 million planned to support working capital, acquisition, and debt reduction.

Financial highlights

• Q4 net sales: SEK 5.2 million (down from SEK 6.7 million in Q4 2024); full-year net sales: SEK 21.1 million (up from SEK 14.5 million in 2024).

• Operating loss Q4: SEK -15.7 million (Q4 2024: SEK -11.9 million); full-year: SEK -46.8 million (2024: SEK -59.3 million).

• Loss after tax Q4: SEK -16.7 million; full-year: SEK -51.3 million.

• Cash and cash equivalents at year-end: SEK 3.5 million (2024: SEK 48.4 million).

• Equity at year-end: SEK 22.6 million (2024: SEK 74.1 million); equity/asset ratio: 26% (2024: 52%).

Outlook and guidance

• Stabilized production and increased throughput expected to drive sales growth in 2026.

• Acquisition of Syntagon AB projected to raise group turnover to SEK 100 million and employee count to nearly 70.

• Management expects positive contribution to earnings and cash flow from Syntagon starting 2026.

• Rights issue and capital raise to secure working capital and support expansion.